Product claims may differ from country to country based on regulations and product approvals. Please contact your country representative for further details.

»  Suche


Erweiterte Suche

»  Quick Links

»  Kontakt

Thermo Fisher Scientific
Clinical Diagnostics
B·R·A·H·M·S GmbH
Neuendorfstrasse 25
D-16761 Hennigsdorf

Tel: +49 - 3302 - 883 - 0
Fax: +49 - 3302 - 883 - 100

Unser Kundenservice bietet Ihnen umfangreiche Unter- stützung und Informationen zu unseren Produkten und Leistungen. weiter
Wir vertreiben unsere Pro- dukte in über 65 Ländern der Welt, finden Sie hier Ihren Ansprechpartner in Ihrem Land! weiter
Wählen Sie aus unserem Produktangebot von ca. 40 speziellen in vitro Parametern die optimale Lösung für Ihre diagnostische Fragestellung. weiter

19.06.2014 - Study Shows Early Rule-Out of Acute Myocardial Infarction using Troponin together with Copeptin is Safe

“Biomarkers in Cardiology 8” study published in European Heart Journal HENNIGSDORF, Germany – (June 17, 2014) – A study conducted by clinicians in leading German, Swiss and Austrian hospitals demonstrates that low-to-intermediate risk patients with suspected Acute Coronary Syndrome (ACS) can safely be discharged earlier from the Emergency Department (ED) using cardiac Troponin together with Copeptin. The study suggests that, by implementing the new process, clinics can better manage overcrowded EDs and increase patient well-being.

05.03.2014 - diaDexus, Inc. Announces Exclusive U.S. Licensing Deal with Thermo Fisher Scientific to Advance Risk Prediction in Heart Failure

-- Company expands cardiovascular pipeline and aims to address large unmet need for prognosis and risk stratification in patients with heart failure --

SOUTH SAN FRANCISCO, Calif.- (March 05, 2014) - diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced an exclusive licensing and supply agreement with Thermo Fisher Scientific Inc., the world leader in serving science with $17 billion in revenues, that will provide diaDexus with the ability to develop and commercialize three independent biomarkers (MR-proADM (midregional pro adrenomedullin), MR-proANP (midregional pro atrial natriuretic peptide), and CT-proET1 (C-terminal pro endothelin-1)) to aid in risk prediction and prognosis for heart failure.

02.10.2013 - Thermo Fisher Scientific and bioMérieux Renew Partnership for Improved Detection of Sepsis Using PCT Biomarker
Procalcitonin (PCT) Immunoassay is Sustained on VIDAS® Instruments

Marcy l'Etoile, France and Hennigsdorf, Germany (October 2, 2012) – bioMérieux and Thermo Fisher Scientific Inc., the world leader in serving science, today announced they have renewed their non-exclusive, long-term, royalty-bearing agreement for Procalcitonin (PCT) testing. This agreement extends a long-standing relationship between the companies for biomarker testing using Thermo Fisher’s PCT product on bioMérieux’s VIDAS® and mini VIDAS® immunoassay platforms, and now also includes the new-generation VIDAS® products.

24.09.2013 - Thermo Fisher Scientific Commends Staunton Family & Senate Committee for Continued Efforts in Raising Sepsis Awareness
Mr. Ciaran Staunton to Speak about Sepsis at Full Senate Hearing on U.S. Efforts to Reduce Healthcare-Associated Infections

(WALTHAM, MA – September 24, 2013) – Thermo Fisher Scientific applauds the tenacity of the Staunton family, as well as Chairman Tom Harkin and Ranking Member Lamar Alexander, for raising the profile of sepsis education among the public, legislators and other government officials.

27.08.2013 - Thermo Fisher Scientific and Siemens Renew Partnership for Improved Detection
of Sepsis Using B•R•A•H•M•S PCT Biomarker
Procalcitonin (PCT) Immunoassay Availability is Continued on ADVIA Centaur® Systems

HENNIGSDORF, Germany – (August 27, 2013) – Hospital laboratories outside the U.S. can benefit from a continued availability of the B•R•A•H•M•S PCT™ assay on ADVIA Centaur® systems, allowing them to diagnose sepsis early and safely.

Veröffentlichungstermine zur wirtschaftlichen Situation des Konzerns
Kongresse & Veranstaltungen
Veranstaltungen und Kongresse auf denen Sie uns finden